Grace Therapeutics, Inc. (GRCE) Earnings History

Grace Therapeutics, Inc. - Q3 FY2026 EarningsBeat

Filed at: Feb 12, 2026, 8:01 AM EST|Read from source

EXECUTIVE SUMMARY

Grace Therapeutics reported its third quarter fiscal year 2026 results, characterized by continued execution on clinical and corporate goals, primarily focused on pre-commercial planning for GTx-104. The company advanced its regulatory review process and presented positive trial data, while managing its cash runway and operational expenses.

POSITIVE HIGHLIGHTS

  • •

    Net loss decreased to $2.3 million, or $0.14 per share, compared to a net loss of $4.2 million, or $0.36 per share, in the prior year period.

    positive
  • •

    Research and development expenses decreased by $1.7 million, primarily due to the completion of the GTx-104 pivotal Phase 3 STRIVE-ON safety clinical trial.

    positive
  • •

    FDA established April 23, 2026 as PDUFA Target Date for review of submission seeking approval for GTx-104.

    positive
  • •

    Phase 3 STRIVE-ON Safety Trial data presented at the 2025 Society of Vascular and Interventional Neurology Annual Meeting showed favorable outcomes for GTx-104.

    positive

CONCERNS & RISKS

  • •

    General and administrative expenses increased by $0.5 million to $2.0 million, primarily due to costs for GTx-104 pre-commercial planning.

    attention
  • •

    Cash and cash equivalents decreased by $3.4 million to $18.7 million as of December 31, 2025, from $22.1 million at March 31, 2025.

    attention
  • •

    The company reported a net loss of $2.3 million for the quarter, indicating ongoing operational costs without revenue generation.

    attention

FINANCIAL METRICS

Revenue
Quarterly
N/A
N/A
Net Income
Quarterly
$-2.31M
+44.3%
Prior year: $-4.16M
Annual (YTD)
$-6.62M
N/A
Prior year: $-10.20M
EPS (Diluted)
Quarterly
$-0.14
+61.1%
Prior year: $-0.36
Operating Income
Quarterly
$-2.45M
+33.9%
Prior year: $-3.70M
Annual (YTD)
$-8.07M
N/A
Prior year: $-13.50M
EPS (Basic)
Quarterly
$-0.14
+61.1%
Prior year: $-0.36

MARGIN ANALYSIS

Margin metrics will be available once backend extracts data from insights_json

MANAGEMENT COMMENTARY

Continued execution on clinical and corporate goals, focused on pre-commercial planning for GTx-104.

— Grace Therapeutics, Inc., Q3 FY2026 2026 Earnings Call

NDA submission for GTx-104 is supported by robust data, including positive results from the STRIVE-ON trial.

— Grace Therapeutics, Inc., Q3 FY2026 2026 Earnings Call

Belief that the U.S. and international patent estate will help maximize the long-term market value of GTx-104.

— Grace Therapeutics, Inc., Q3 FY2026 2026 Earnings Call

Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.

OPERATIONAL METRICS

Weighted Average Number Of Shares Outstanding
16.9M
+47.2% YoY
Prior year: 11.5M
shares

Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.